Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Collegium Pharmaceutical (Nasdaq: COLL) announced inducement equity grants made on June 1, 2026 under its 2026 Inducement Plan. The company granted 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees, with three-year, service-based vesting, under Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- 50,305 RSUs granted to 34 new non-executive hires
- Three-year vesting schedule encourages employee retention and alignment
- 2026 Inducement Plan adopted May 11, 2026 to support hiring
Negative
- Future issuance of up to 50,305 shares may increase share count
- Equity awards granted outside stockholder-approved equity incentive plan
Key Figures
Market Reality Check
Peers on Argus
Sector peers like PCRX (+1.8%) and AMPH (+2.08%) were modestly higher, while momentum scanner names were mixed (TLRY +5.98%, BGM -8.31%). With COLL up 5.25% on an administrative RSU announcement, the move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference participation | Neutral | -0.3% | Announcement of Jefferies Global Healthcare Conference fireside chat and webcast. |
| May 12 | Product acquisition | Positive | -0.3% | Completion of AZSTARYS acquisition with raised 2026 revenue and EBITDA guidance. |
| May 07 | Quarterly earnings | Positive | +7.7% | Q1 2026 revenue growth, solid EBITDA, cash balance, and AZSTARYS closing outlook. |
| Apr 23 | Earnings date set | Neutral | -2.4% | Scheduling of Q1 2026 earnings release and accompanying conference call. |
| Apr 08 | Investor conferences | Neutral | +2.0% | Participation in Needham virtual healthcare conference and Piper Sandler symposium. |
Most news events showed price moves broadly aligned with their tone, with one divergence on a major acquisition and guidance raise.
Over recent months, Collegium reported strong Q1 2026 results with product revenues of $193.5M, JORNAY PM revenue of $38.9M, adjusted EBITDA of $103.9M, and cash of $421.8M, which coincided with a +7.72% move. It then completed the $650M AZSTARYS acquisition and raised 2026 revenue and EBITDA guidance, yet shares slipped slightly. Several conference and investor-relations updates produced only modest reactions, suggesting the market has focused most on core financial and M&A developments.
Market Pulse Summary
This announcement details inducement equity awards totaling 50,305 RSUs to 34 newly hired non-executive employees under a 2026 Inducement Plan, vesting over roughly three years starting June 10, 2027. Such grants modestly increase share-based compensation but are common for talent recruitment. In context of recent strong Q1 2026 results and the AZSTARYS acquisition, investors may watch overall dilution trends, insider activity, and future earnings updates for a fuller picture.
Key Terms
restricted stock units financial
rsus financial
nasdaq listing rule 5635(c)(4) regulatory
equity incentive plan financial
AI-generated analysis. Not financial advice.
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan).
The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company’s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee’s continued service with the Company through each applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company’s common stock.
The above-described RSUs were granted outside of the Company's stockholder-approved equity incentive plan pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the Board) on May 11, 2026 as a material inducement to the individuals entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.
Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
